Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity

Abstract

SARS-CoV-2 can mutate and evade immunity, with consequences for efficacy of emerging vaccines and antibody therapeutics. Here, we demonstrate that the immunodominant SARS-CoV-2 spike (S) receptor binding motif (RBM) is a highly variable region of S and provide epidemiological, clinical, and molecular characterization of a prevalent, sentinel RBM mutation, N439K. We demonstrate N439K S protein has enhanced binding affinity to the hACE2 receptor, and N439K viruses have similar in vitro replication fitness and cause infections with similar clinical outcomes as compared to wild type. We show the N439K mutation confers resistance against several neutralizing monoclonal antibodies, including one authorized for emergency use by the US Food and Drug Administration (FDA), and reduces the activity of some polyclonal sera from persons recovered from infection. Immune evasion mutations that maintain virulence and fitness such as N439K can emerge within SARS-CoV-2 S, highlighting the need for ongoing molecular surveillance to guide development and usage of vaccines and therapeutics.

Cited by papers we hold 23

• Characterization of Two Heterogeneous Lethal Mouse-Adapted SARS-CoV-2 Variants Recapitulating Representative Aspects of Human COVID-19 · 2022
  Not checked
• A Detailed Overview of Immune Escape, Antibody Escape, Partial Vaccine Escape of SARS-CoV-2 and Their Emerging Variants With Escape Mutations · 2022
  No notice
• COVID-19 vaccine development: milestones, lessons and prospects · 2022
  No notice
• The Impact of Evolving SARS-CoV-2 Mutations and Variants on COVID-19 Vaccines · 2022
  No notice
• Deep mutational scans for ACE2 binding, RBD expression, and antibody escape in the SARS-CoV-2 Omicron BA.1 and BA.2 receptor-binding domains · 2022
  No notice
• Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection · 2022
  No notice
• Prolonged evolution of the human B cell response to SARS-CoV-2 infection · 2021
  No notice
• Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study · 2021
  No notice
• Sex Differences in Lung Imaging and SARS-CoV-2 Antibody Responses in a COVID-19 Golden Syrian Hamster Model · 2021
  Not checked
• Experimental Evidence for Enhanced Receptor Binding by Rapidly Spreading SARS-CoV-2 Variants · 2021
  No notice
• A point-of-care lateral flow assay for neutralising antibodies against SARS-CoV-2 · 2021
  Not checked
• SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern · 2021
  No notice
• Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England · 2021
  No notice
• Emerging SARS-CoV-2 Variants: A Review of Its Mutations, Its Implications and Vaccine Efficacy · 2021
  No notice
• mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection · 2021
  No notice
• Prospective mapping of viral mutations that escape antibodies used to treat COVID-19 · 2021
  No notice
• Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies · 2021
  Corrected
• Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants · 2021
  No notice
• A plasmid DNA-launched SARS-CoV-2 reverse genetics system and coronavirus toolkit for COVID-19 research · 2021
  No notice
• SARS-CoV-2 within-host diversity and transmission · 2021
  No notice

and 3 more

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.